Literature DB >> 1900790

Exacerbation of partial seizures and onset of nonepileptic myoclonus with carbamazepine.

A Dhuna1, A Pascual-Leone, D Talwar.   

Abstract

A child had two to three generalized tonic-clonic (GTC) seizures per week unresponsive to phenobarbital (PB) and valproate (VPA). Interictal EEG demonstrated left occipital spikes. When carbamazepine (CBZ) therapy was started, he developed very frequent (4-6/day) complex partial seizures (CPS) characterized on ictal EEG by focal right temporal lobe discharges. The seizure exacerbation, which was associated with development of nonepileptic, multifocal myoclonus, resolved 24 h after CBZ was discontinued. The exacerbation occurred with therapeutic CBZ serum levels, but may have been related to the toxic levels of carbamazepine-10, 11-epoxide (CBZE).

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1900790     DOI: 10.1111/j.1528-1157.1991.tb05255.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  6 in total

Review 1.  Drug-induced movement disorders.

Authors:  F J Jiménez-Jiménez; P J García-Ruiz; J A Molina
Journal:  Drug Saf       Date:  1997-03       Impact factor: 5.606

Review 2.  Antiseizure Drugs and Movement Disorders.

Authors:  Michel Sáenz-Farret; Marina A J Tijssen; Dawn Eliashiv; Robert S Fisher; Kapil Sethi; Alfonso Fasano
Journal:  CNS Drugs       Date:  2022-07-21       Impact factor: 6.497

Review 3.  Drug-induced myoclonus: frequency, mechanisms and management.

Authors:  Félix Javier Jiménez-Jiménez; Inmaculada Puertas; María de Toledo-Heras
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 4.  Guidelines for treating epilepsy in the age of felbamate, vigabatrin, lamotrigine, and gabapentin.

Authors:  K D Laxer
Journal:  West J Med       Date:  1994-09

5.  Investigation and management of loss of efficacy of an antiepileptic medication using carbamazepine as an example.

Authors:  K K Jain
Journal:  J R Soc Med       Date:  1993-03       Impact factor: 18.000

6.  Incidence of seizure exacerbation and seizures reported as adverse events during adjunctive treatment with eslicarbazepine acetate: A pooled analysis of three Phase III controlled trials.

Authors:  Mar Carreño; Selim Benbadis; Francisco Rocha; David Blum; Hailong Cheng
Journal:  Epilepsia Open       Date:  2017-11-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.